Broncus Holding (HKSE:02216) Moat Score: 0/10 (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02216 Broncus Holding Corp HKSE:02216
43 GF Score
Price HK$0.66
GF Value HK$0.15
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Broncus Holding Moat Score?

Broncus Holding has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Broncus Holding has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Broncus Holding might have No Moat - No discernible moat.

Broncus Holding  (HKSE:02216) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Broncus Holding Moat Score Related Terms

HKSE:02216
43GF Score
Broncus Holding Corp HKSE:02216
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Broncus Holding (HKSE:02216) Overvalued in 2026?

Based on GuruFocus' analysis, Broncus Holding stock appears to be overvalued. The current stock price of HK$0.66 is trading 336.7% above its estimated GF Value™ of HK$0.15. GuruFocus considers Broncus Holding to be Significantly Overvalued.

Key valuation signals for HKSE:02216:

  • Moat Score: 0
  • GF Value™: HK$0.15 vs. price of HK$0.66 (336.7% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the HKSE:02216 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Broncus Holding Business Description

Address No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN
Broncus Holding Corp is focused on provision of interventional treatment of Chronic Obstructive Pulmonary Disease and lung cancer. It engages in the field of Interventional Pulmonology, providing solutions for lung diseases in China and globally. Its products portfolio includes the InterVapor Thermal Vapor Treatment System the only implantable medical device to treat COPD; BroncAblate Radiofrequency Ablation System the transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation Radiofrequency Ablation System the self-developed targeted radiofrequency ablation system in China to reduce the risk of acute exacerbation of COPD. Geographically, the company operates in Chinese Mainland; European Union; and Other Regions.
43GF Score

Get the complete analysis for HKSE:02216

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.66
Price
HK$0.15
GF Value